Shares of TESARO Inc (NASDAQ:TSRO) have been given a consensus recommendation of “Buy” by the twenty-eight analysts that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, ten have given a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $149.78.
Several equities analysts have recently issued reports on the stock. Robert W. Baird reaffirmed a “neutral” rating and set a $125.00 price target on shares of TESARO in a research note on Monday, October 2nd. Cann reaffirmed a “buy” rating and set a $199.00 price target on shares of TESARO in a research note on Friday, September 8th. Citigroup reaffirmed a “buy” rating and set a $216.00 price target on shares of TESARO in a research note on Monday, September 11th. Oppenheimer reaffirmed a “buy” rating and set a $199.00 price target on shares of TESARO in a research note on Sunday, September 10th. Finally, Zacks Investment Research downgraded shares of TESARO from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th.
TESARO (TSRO) traded down $7.25 during mid-day trading on Tuesday, hitting $75.62. 2,281,591 shares of the stock traded hands, compared to its average volume of 1,384,050. The company has a market capitalization of $4,110.00, a P/E ratio of -8.97 and a beta of 1.52. TESARO has a 12-month low of $74.57 and a 12-month high of $192.94. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.73 and a quick ratio of 4.35.
In other TESARO news, SVP Martin H. Jr. Huber sold 829 shares of TESARO stock in a transaction on Monday, December 4th. The shares were sold at an average price of $85.24, for a total value of $70,663.96. Following the completion of the sale, the senior vice president now directly owns 8,101 shares of the company’s stock, valued at $690,529.24. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 34.60% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of TSRO. Advisors Asset Management Inc. grew its holdings in shares of TESARO by 15.4% during the second quarter. Advisors Asset Management Inc. now owns 4,076 shares of the biopharmaceutical company’s stock valued at $570,000 after buying an additional 543 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of TESARO during the second quarter valued at about $351,000. Legal & General Group Plc grew its holdings in shares of TESARO by 254.5% during the second quarter. Legal & General Group Plc now owns 37,218 shares of the biopharmaceutical company’s stock valued at $5,206,000 after buying an additional 26,719 shares during the last quarter. BNP Paribas Arbitrage SA grew its holdings in shares of TESARO by 317.8% during the second quarter. BNP Paribas Arbitrage SA now owns 3,326 shares of the biopharmaceutical company’s stock valued at $465,000 after buying an additional 2,530 shares during the last quarter. Finally, KBC Group NV acquired a new position in shares of TESARO during the second quarter valued at about $707,000.
ILLEGAL ACTIVITY WARNING: “TESARO Inc (TSRO) Given Consensus Recommendation of “Buy” by Brokerages” was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.chaffeybreeze.com/2018/01/02/tesaro-inc-tsro-given-consensus-recommendation-of-buy-by-brokerages.html.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.